Fungi That Infect Humans
Overview
Affiliations
Fungi must meet four criteria to infect humans: growth at human body temperatures, circumvention or penetration of surface barriers, lysis and absorption of tissue, and resistance to immune defenses, including elevated body temperatures. Morphogenesis between small round, detachable cells and long, connected cells is the mechanism by which fungi solve problems of locomotion around or through host barriers. Secretion of lytic enzymes, and uptake systems for the released nutrients, are necessary if a fungus is to nutritionally utilize human tissue. Last, the potent human immune system evolved in the interaction with potential fungal pathogens, so few fungi meet all four conditions for a healthy human host. Paradoxically, the advances of modern medicine have made millions of people newly susceptible to fungal infections by disrupting immune defenses. This article explores how different members of four fungal phyla use different strategies to fulfill the four criteria to infect humans: the Entomophthorales, the Mucorales, the Ascomycota, and the Basidiomycota. Unique traits confer human pathogenic potential on various important members of these phyla: pathogenic Onygenales comprising thermal dimorphs such as and ; the spp. that infect immunocompromised as well as healthy humans; and important pathogens of immunocompromised patients-, , and spp. Also discussed are agents of neglected tropical diseases important in global health such as mycetoma and paracoccidiomycosis and common pathogens rarely implicated in serious illness such as dermatophytes. Commensalism is considered, as well as parasitism, in shaping genomes and physiological systems of hosts and fungi during evolution.
Alves V, Zamith-Miranda D, Frases S, Nosanchuk J J Fungi (Basel). 2025; 11(2).
PMID: 39997385 PMC: 11856446. DOI: 10.3390/jof11020093.
Jayaweera S, Van T, Dias D J Xenobiot. 2025; 15(1).
PMID: 39997375 PMC: 11856389. DOI: 10.3390/jox15010032.
Anti-biofilm effect of clove oil against : A systematic review.
Sangeeta J, Aishwarya O, Omkar D, Madhura N J Oral Maxillofac Pathol. 2025; 28(4):665-671.
PMID: 39949693 PMC: 11819647. DOI: 10.4103/jomfp.jomfp_225_24.
Human Fungal Infections: Diagnostic and Therapeutic Challenges.
Vyzantiadis T, Gavriilaki E, Tragiannidis A J Fungi (Basel). 2025; 11(1.
PMID: 39852484 PMC: 11766858. DOI: 10.3390/jof11010066.
The impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance.
Kozubowski L, Berman J FEMS Microbiol Rev. 2025; 49.
PMID: 39809571 PMC: 11756289. DOI: 10.1093/femsre/fuaf001.